Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
Seems that Rituxan and Zevalin make a good complement to each other...

If IDEC can convince oncologists that their proposed Zevalin+Rituxan regimen is better than Rituxan alone, it may entrench Rituxan in the market and make it more difficult for Bexxar to steal market share. From listening to Genentech's webcast in February, I got the impression from them that Bexxar will be solely a salvage therapy for use in patients that did not respond to Rituxan. We'll have to wait and see how this plays out, though I'm not too concerned given the stocked pipeline of late-stage candidates.

Charly
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.